Table 3 LVMI and blood pressure change at 48 weeks stratified by treatment and genotype
From: Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy
Irbesartan | Atenolol | |||||
|---|---|---|---|---|---|---|
Lys/Lys (n = 3) | Lys/Arg (n = 16) | Arg/Arg (n = 24) | Lys/Lys (n = 6) | Lys/Arg (n = 19) | Arg/Arg (n = 22) | |
DBP change (mmHg) | -14.8 [8.1] | -18.2 [2.3] | -19.5 [1.5] | -19.6 [3.3] | -12.8 [1.8] | -17.5 [1.4] |
DBP change (mmHg) | -14.8 [8.1] | -18.2 [2.3] | -19.5 [1.5] | -19.6 [3.3] | -12.8 [1.8] | -17.5 [1.4] |
SBP change (mmHg) | -9.1 [15.3] | -26.3 [5.1] | -31.5 [4.1] | -27.1 [5.9] | -19.3 [3.7] | -21.2 [3.3] |
LVMI change (g/m2) | -12.2 [15.3] | -14.9 [6.6] | -33.6 [5.4] | -25.2 [8.6] | -9.0 [4.8] | -15.5 [4.7] |
LVMI change (g/m2) – multivariate | -31.6 [11.6] | -16.7 [4.5] | -30.1 [3.6] * | -22.2 [9.6] | -13.3 [5.0] | -12.6 [4.5] |